The level of ctDNA has been quantified by BEAMing (beads, emulsions, amplification, and magnetics) and compared to carcinoembryonic antigen marker (CEA), routinely used in the management of the disease in subjects with CRC [42]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.